Scarica l'app Stockscreener
8.32
1.09%
0.09
Dopo l'orario di chiusura:
8.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Needham Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month HighHere's What Happened - MarketBeat
Dow Update: Is Solid Biosciences Inc part of any ETF2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Sell Signal: Can Solid Biosciences Inc maintain its current growth rate2026 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn
Solid Biosciences Inc. Files Form 8-K with SEC Detailing Company Information and No Amendments as of April 10, 2026 - Minichart
Solid Biosciences reclassifies board member Ilan Ganot to Class I director By Investing.com - Investing.com Australia
Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com
Solid Biosciences Adjusts Board Classes in Governance Move - TipRanks
Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan
Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan
Activity Recap: Can Solid Biosciences Inc maintain its current growth rateOil Prices & Long-Term Safe Return Strategies - baoquankhu1.vn
Aug Gainers: What are Solid Biosciences Incs earnings expectationsWeekly Trade Analysis & Capital Efficient Trade Techniques - baoquankhu1.vn
Solid Biosciences to Participate at Upcoming Investor Conferences - marketscreener.com
Solid Biosciences CEO speaks April 14; investor meetings follow - Stock Titan
Solid Biosciences (NASDAQ:SLDB) Trading 6.4% HigherHere's What Happened - MarketBeat
SLDB PE Ratio & Valuation, Is SLDB Overvalued - Intellectia AI
Solid Biosciences Stock: Gene Therapy Pipeline and Strategic Position in Neuromuscular Disorders - AD HOC NEWS
Director at Solid Biosciences (NASDAQ: SLDB) exercises RSUs - Stock Titan
[EFFECT] Solid Biosciences Inc. SEC Filing - Stock Titan
Big Picture: Whats the beta of Solid Biosciences Inc stockMarket Growth Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Trading Down 6.7%Here's Why - MarketBeat
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Aug Analyst Calls: Is Solid Biosciences Inc part of any ETF2026 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Up 5.5% After Analyst Upgrade - MarketBeat
Truist Financial Upgrades Solid Biosciences (NASDAQ:SLDB) to "Strong-Buy" - MarketBeat
JPMorgan Chase & Co. Raises Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - GuruFocus
HC Wainwright Expects Higher Earnings for Solid Biosciences - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20 - Moomoo
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Faces Pricing Challenges Amid Changing Gene Therapy Economics Due to Updated Regulations - Bitget
Guggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendation - MSN
Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows - TipRanks
RA CAPITAL MANAGEMENT, L.P. Reduces Stake in Solid Biosciences Inc - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (SLDB) with B - GuruFocus
Will Solid Biosciences Inc stock recover after earnings2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Gap UpWhat's Next? - MarketBeat
Solid Bio stock wins new Buy at Guggenheim (SLDB:NASDAQ) - Seeking Alpha
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from Chardan Capital - MarketBeat
Solid Biosciences (SLDB) Receives Maintained 'Buy' Rating from C - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Solid Biosciences (SLDB) Receives Buy Rating and Positive Outloo - GuruFocus
Guggenheim Initiates Solid Biosciences at Buy With $26 Price Target - marketscreener.com
SLDB: Needham Reiterates 'Buy' Rating with Price Target of $19.0 - GuruFocus
Solid Biosciences Inc. 2025 Annual Report: Advancing Gene Therapy for Neuromuscular and Cardiac Diseases - Minichart
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Solid Biosciences (SLDB) Strengthens Financial Position with Inc - GuruFocus
Solid Biosciences (NASDAQ: SLDB) resale registration for 42.8M shares - Stock Titan
[S-3] Solid Biosciences Inc. Shelf Registration Statement | SLDB SEC FilingForm S-3 - Stock Titan
Solid Biosciences Reports Positive Interim Data for SGT-003 and Advances Clinical Programs in Duchenne Muscular Dystrophy, Friedreich’s Ataxia, and CPVT - Quiver Quantitative
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewswire
Solid targets Phase 3 Duchenne dosing in April after positive data - Stock Titan
Gene therapy pipeline at Solid Biosciences (NASDAQ: SLDB) targets Duchenne and cardiac disease - Stock Titan
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration - Traders Union
According to the latest disclosure documents from the U.S. Securities and Exchange Commission, biotechnology company Solid Biosciences has submitted a resale prospectus, and a certain shareholder of the company plans to resell up to 1.3 million shares o - Bitget
Geopolitics Watch: What analysts say about Solid Biosciences Inc stockWeekly Trade Review & Reliable Entry Point Alerts - baoquankhu1.vn
PERCEPTIVE ADVISORS LLC Increases Stake in Solid Biosciences Inc - GuruFocus
RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):